Comparative effectiveness of CDK4/6 inhibitor plus endocrine therapy combinations in HR-positive, HER2-negative metastatic breast cancer: the inspiration 01 study.
Saved in:
| Title: | Comparative effectiveness of CDK4/6 inhibitor plus endocrine therapy combinations in HR-positive, HER2-negative metastatic breast cancer: the inspiration 01 study. |
|---|---|
| Authors: | Jia Y; Department of Breast Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Breast Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University, Ministry of Education, Tianjin, China., Zhang J; Department of Breast Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Breast Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University, Ministry of Education, Tianjin, China., Wang X; Department of Breast Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Breast Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University, Ministry of Education, Tianjin, China., Hao C; Department of Breast Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Breast Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University, Ministry of Education, Tianjin, China., Wang C; Department of Breast Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Breast Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University, Ministry of Education, Tianjin, China., Li S; Department of Breast Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Breast Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University, Ministry of Education, Tianjin, China., Lu N; Department of Breast Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Breast Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University, Ministry of Education, Tianjin, China., Dong G; Department of Breast Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Breast Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University, Ministry of Education, Tianjin, China., Zhao W; Department of Breast Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Breast Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University, Ministry of Education, Tianjin, China., Jia Y; Department of Breast Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Breast Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University, Ministry of Education, Tianjin, China., Huang L; Department of Medical Oncology, The First Hospital of Putian City, Putian, Fujian, China., Gu J; Department of Pharmacy, Tianjin Medical University Baodi Hospital, Tianjin, China., Shi Y; Department of Breast Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Breast Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University, Ministry of Education, Tianjin, China., Tong Z; Department of Breast Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Breast Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University, Ministry of Education, Tianjin, China. |
| Source: | Frontiers in pharmacology [Front Pharmacol] 2026 Apr 13; Vol. 17, pp. 1757379. Date of Electronic Publication: 2026 Apr 13 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1663-9812 |
|---|---|
| DOI: | 10.3389/fphar.2026.1757379 |
